Obstacles to Brain Tumor Therapy: Key ABC Transporters

@article{Wijaya2017ObstaclesTB,
  title={Obstacles to Brain Tumor Therapy: Key ABC Transporters},
  author={J. Wijaya and Y. Fukuda and J. Schuetz},
  journal={International Journal of Molecular Sciences},
  year={2017},
  volume={18}
}
The delivery of cancer chemotherapy to treat brain tumors remains a challenge, in part, because of the inherent biological barrier, the blood–brain barrier. While its presence and role as a protector of the normal brain parenchyma has been acknowledged for decades, it is only recently that the important transporter components, expressed in the tightly knit capillary endothelial cells, have been deciphered. These transporters are ATP-binding cassette (ABC) transporters and, so far, the major… Expand
ABC Transporters at the Blood–Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas
TLDR
The implication of ABC transporters in glioma and the BBTB in drug resistance and the strategies to improve the delivery of CNS anticancer drugs are summarized. Expand
The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
TLDR
A deeper understanding of the BBB and BTB through the application of single-cell sequencing and imaging techniques, and the development of biomarkers of BBB integrity along with systems biology approaches, should enable new personalized treatment strategies for primary brain malignancies and brain metastases. Expand
Overview of Current Drug Delivery Methods Across the Blood–Brain Barrier for the Treatment of Primary Brain Tumors
TLDR
More research is needed to optimize and develop new drug delivery techniques to improve survival of patients with primary brain tumors, and drug delivery methods that combine strategies such as focused ultrasound and nanoparticles might be a more successful approach. Expand
Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders.
TLDR
The signaling pathways that regulate the expression and activity of P-gp, BCRP and MRPs subfamilies of transporters are reviewed, with particular attention at the BBB level, and their mis-regulation in neurological disorders are reviewed. Expand
Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma.
TLDR
It is shown that the β-amphetaminylated cationic lipid nanoparticles are nontoxic and can cross the blood-brain barrier presumably through active transcytosis, and their therapeutic promise against glioblastoma is delineated. Expand
Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach
TLDR
Results indicate that the nasal administration of NE as a CD73 siRNA delivery system offered an efficient means of gene knockdown and may represent a potential alternative for glioblastoma treatment. Expand
Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas
TLDR
The potential of a novel approach to increase the effectiveness of platinum-based drugs against glioblastomas is emphasized, as a solution to overcome obstacles in overcoming brain tumors. Expand
Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism
TLDR
This study finds that ABCB5 is expressed in primary GBM tumors, in which its expression was significantly correlated with the CSC marker protein CD133 and with overall poor survival, and identifies it as a GBM chemoresistance marker. Expand
CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model
TLDR
Results suggest that nasal administration of NE-siRNA CD73 exhibits higher antiglioma effect when compared to TMZ, however, no synergistic or additive in vivo was promoted by the therapeutic regimen employed in this study. Expand
Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients
TLDR
The upregulation of both ABC transporters in the brain may explain multidrug resistance in ALS patients and has implications for the use of both approved and experimental therapeutics. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 165 REFERENCES
Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm.
  • E. Gerstner, R. Fine
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
The hypothesis is that metastatic brain tumors from tumors with intrinsically low P-gp expression (eg, lung, melanoma, and untreated breast) may be more permeable to natural product chemotherapy drugs than gliomas. Expand
Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors
TLDR
This review has elucidated some critical insights into the composition and function of blood brain barrier and along with it it has discussed the effective methods for delivery of drugs to the brain and therapeutic strategies overcoming the barrier. Expand
Impact of Blood–Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases
TLDR
This study provides the first direct evidence that nonpermeable brain micro- and macrometastases can effectively be targeted by a drug designed to cross the BBB, and is a promising agent in preventing or treating brain metastases in patients. Expand
Active Efflux of Dasatinib from the Brain Limits Efficacy against Murine Glioblastoma: Broad Implications for the Clinical Use of Molecularly Targeted Agents
TLDR
Data show that active efflux is a relevant obstacle to treating glioblastoma and provide a plausible mechanistic basis for the clinical failure of numerous drugs that are BCRP/Pgp substrates. Expand
Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
TLDR
This work shows that the BTB remains a significant impediment to standard chemotherapeutic delivery and efficacy in experimental brain metastases of breast cancer, and new brain permeable drugs will be needed. Expand
Human brain tumors: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells
TLDR
It is demonstrated that the MDR1 gene can be detected in all grade tumor brain malignancies and in endothelial cells of newly formed capillaries, thus, impairing drug access at the tumor cell level. Expand
Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
TLDR
Methods to overcome the blood-brain tumor barrier barrier (BBTB) are provided, including osmotic blood- brain barrier disruption (BBBD), bradykinin receptor-mediated BBTB opening, inhibition of multidrug efflux transporters, receptor- mediated transport systems and physiological circumvention of the BBTB. Expand
BCRP at the blood-brain barrier: genomic regulation by 17β-estradiol.
TLDR
The long-term effect of 17β-estradiol induces the down-regulation of BCRP on transcriptional and translational levels via the activation of ERβ in rat brain capillaries after 6 h demonstrating that the transporter is down-regulated via a genomic pathway. Expand
The role of ABC transporters in clinical practice.
TLDR
Optimism is warranted with the advent of potent, nontoxic inhibitors and new treatment strategies, including the combination of new targeted therapies with therapies aimed at the prevention of drug resistance. Expand
Localisation of breast cancer resistance protein in microvessel endothelium of human brain
TLDR
Investigation of other ABC transporters in both normal and tumour human brain tissue and the presence of breast cancer resistance protein (BCRP) demonstrate that BCRP is located at the blood–brain barrier, mainly at the luminal surface of microvessel endothelium. Expand
...
1
2
3
4
5
...